A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

NCT04254107 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

133

Enrollment

INDUSTRY

Sponsor class

Stopped Study closed due to portfolio prioritization

Conditions

Non-small Cell Lung Cancer
Gastric Carcinoma
Gastroesophageal Junction Carcinoma
Classical Hodgkin Lymphoma
Diffuse Large B-cell Lymphoma
Peripheral T-cell Lymphoma
Cutaneous Melanoma
Head and Neck Squamous Cell Carcinoma
Bladder Cancer
Ovarian Cancer
Triple Negative Breast Cancer
Cervical Cancer

Interventions

DRUG: SEA-TGT
DRUG: sasanlimab
DRUG: brentuximab vedotin

Sponsor

Seagen Inc.